---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-055181"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:48:38.588851+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics Phase 1 data: VCN-01 well-tolerated in retinoblastoma; eye preserved in 3 of 9 patients

## Summary
- VCN-01 intravitreal injection at 2E+10 vp/eye was well-tolerated; no retinal toxicity or DLTs; main AE Grade 1-2 uveitis.
- Four of nine patients had improvement in vitreous seed density; 3 avoided enucleation with follow-up up to 49 months.
- No Grade >=3 ocular or systemic toxicities; selective replication in tumor cells confirmed by immunohistochemistry.
- RP2D defined as 2 doses of 2E+10 vp/eye; VCN-01 genomes in aqueous humor correlated with vitreous seed persistence.

## SEC filing metadata
- accession: 0001104659-25-055181
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925055181/0001104659-25-055181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925055181/tm2516499d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-055181
- JSON: https://secwatch.observer/filing/0001104659-25-055181.json
- Plain text: https://secwatch.observer/filing/0001104659-25-055181.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.